De-novo and acquired resistance to immune checkpoint targeting.

By N. Syn, M. Teng, T. Mok, R. Soo. The Lancet Oncology, 2017

665 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “Thus far, CTLA-4, PD-1 and PD-L1 have achieved significant clinical efficacy and have been approved for the treatment of many types of cancer.(144) However, the problem of immune drug resistance persists.”